Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Oct 2025

Liu Feng-Tao, Li Xin-Yi, Lu Jia-Ying, Zuo Chuan-Tao

Abstract excerpt

INTRODUCTION: While amyloid cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers are considered interchangeable indicators of Alzheimer's disease (AD) pathology, biomarker discrepancies can occur but remain poorly characterized. METHODS: We evaluated 18F-florbetapir amyloid PET, 18F-Florzolotau PET (tau pathology), magnetic resonance imaging (MRI) findings, and CSF biomarkers in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloid beta-Protein Precursor

Share to Aniline Compounds

Share to Magnetic Resonance Imaging

Share to Peptide Fragments

Share to Positron-Emission Tomography

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41117348
DOI: 10.1002/alz.70823
PMCID: PMC12538635

Genes

APP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome.PMID 41117348Read ↗

Real-world evaluation of Armstrong's criteria in corticobasal degeneration: Phenotypic overlap and diagnostic challenges.Semantic proximity Read ↗

[ 18 F]-Flortaucipir PET/MRI Supports a 4R Tauopathy Phenotype in Corticobasal Degeneration.Semantic proximity Read ↗

Atypical Alzheimer's disease phenotypes with normal or borderline PET biomarker profiles.Semantic proximity Read ↗

Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier.Semantic proximity Read ↗

18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.Semantic proximity Read ↗

Amyloid PET Burden, CSF Biomarkers, and APOE Genotype in People With Iatrogenic and Sporadic Cerebral Amyloid Angiopathy.Semantic proximity Read ↗

A Peculiar Tau Accumulation Pattern Identified Via 18 F-Florzolotau PET Imaging in a Patient With Frontotemporal Dementia Caused by a Mutation in the MAPT Gene.Semantic proximity Read ↗

Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.Semantic proximity Read ↗

Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical PracticeSemantic proximity Read ↗

Neuroradiologic and clinicopathologic features of oculoleptomeningeal type amyloidosis.Semantic proximity Read ↗

Single-photon emission computed tomography 123I-ioflupane imaging in CSF1R mutation carriers.Semantic proximity Read ↗

[18F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.